


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 814073526 US, on the date shown below in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 29, 2006

Signature: 

(Grace Y. Y.)

Docket No.: 511582003500
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mary FARIS et al.

Application No.: 09/809,638

Confirmation No.: 5083

Filed: March 14, 2001

Art Unit: 1643

For: 125P5C8: A TISSUE SPECIFIC PROTEIN
HIGHLY EXPRESSED IN VARIOUS
CANCERS

Examiner: A. Harris

RENEWED PETITION UNDER RULE 37 CFR §1.47 OR
ALTERNATIVELY UNDER 37 CFR §1.183
REGARDING STEVE CHAPPELL MITCHELL

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §1.47 or 1.183, assignee and real-party-in-interest, Agensys, Inc. and co-inventors Pia M. CHALLITA-EID, Daniel E.H. AFAR, Arthur B. RAITANO, and Aya JAKOBOVITS respectfully state that the whereabouts of co-inventor Steve Chappell Mitchell are unknown, that he is therefore unable to join in the prosecution of the present application, and request that the Declaration under 37 C.F.R. § 1.131 be accepted without the signature of one of the co-inventors, Mr. Mitchell.

The pending claims and Declaration under 37 C.F.R. § 1.131 were presented to Mr. Mitchell for review and execution at his last known address. The papers provided for Mr.

Mitchell's review were returned, unopened. Below is a brief description of attempts made to contact Mr. Mitchell regarding the Declaration.

1. Mr. Mitchell was an employee of Agensys from November 1997 to June 29, 2001.
2. Mr. Mitchell's last known address is:
601 Linden Place
Loft #311
Evanston, IL 60201.
3. On 27 January 2006, a package containing a letter requesting Mr. Mitchell's signature on a Declaration under 37 C.F.R. 1.131 was mailed via DHL / Worldwide Express, to Steven Chappell Mitchell, at his last known address. The package also contained three exhibits which confirmed the need to file a 1.131 Declaration and a return DHL envelope for his convenience in returning the executed Declaration. *See Exhibit A*.
4. The package was successfully delivered to the address provided. Attached hereto as Exhibit B is a copy of the delivery confirmation sent by DHL / Worldwide Express indicating that the package was delivered 30 January 2006 at 10:32 a.m. No response was ever received.
5. On 03 March 2006, another attempt to contact Mr. Mitchell was made via DHL / Worldwide Express, at his last known address, and a second package containing a letter that requested his signature on a Declaration under 37 C.F.R. 1.131. The package also contained three exhibits which confirmed the need to file a 1.131 Declaration and a return DHL envelope for his convenience in returning the executed Declaration. *See Exhibit C*.
6. The package was successfully delivered to the address provided. Attached hereto as Exhibit D is a copy of the delivery confirmation sent by DHL / Worldwide Express indicating that the package was delivered 06 March 2006 at 11:35 a.m. No response was ever received.
7. There is no forwarding telephone number on record at his former place of employment for Mr. Mitchell. Thus, it has not been possible to contact Mr. Mitchell telephonically.

8. After diligence effort, Applicants' representative has not been able to locate Mr. Mitchell to obtain his signature on the Declaration submitted under 37 C.F.R. 1.131. As such, Applicants petition to waive the rules to allow the remaining inventors to swear behind the cited reference.

In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 511582003500. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: September 29, 2006

Respectfully submitted,

By 

James J. Mullen III, Ph.D.

Registration No.: 44,957

MORRISON & FOERSTER LLP

12531 High Bluff Drive

Suite 100

San Diego, California 92130-2040

(858) 720-7940

27 January 2006

Sent via Worldwide Express / DHL

Mr. Steven Chappell Mitchell
601 Linden Place
#311 loft
Evanston, IL 60201

RE: U.S. Patent Application:
Title: 125P5C8: A TISSUE SPECIFIC PROTEIN HIGHLY EXPRESSED IN
VARIOUS CANCERS
Serial No.: 09/809,638
Our Ref.: 51158-20035.00

Dear Steve:

Please find enclosed a Declaration under 37 C.F.R. §1.131 for the above-referenced patent application for which you are listed as an inventor. The need for a §1.131 Declaration came about when; during prosecution of the above-referenced case, the Patent Examiner cited WO/200270539 as allegedly anticipating our claims.

37 C.F.R. 1.131(a) states in pertinent part:

"When any claim of an application is rejected, the inventor of the subject matter of the rejected claim may submit an appropriate oath or declaration to establish invention of the subject matter of the rejected claim prior to the effective date of the reference or activity on which the rejection is based."

Accordingly, please find enclosed a copy of the 1.31 Declaration for your execution on the above-referenced matter, a copy of a document demonstrating reduction to practice prior to the WO/200270539 document which has an effective date of 05 March 2001.

Please review the enclosed documents and sign and date the enclosed §1.131 Declaration and return it to us as soon as possible. I have enclosed a return DHL envelope for your convenience.

If you have any questions feel free to contact me at 310.820.8029 ext. 205.

With regards,


Shane M. Popp J.D., LL.M.
Manager, Legal

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mary FARIS, et al.

Application No.: 09/809,638

Filed: March 14, 2001

For: 125P5C8: A TISSUE SPECIFIC PROTEIN
HIGHLY EXPRESSED IN VARIOUS
CANCERS

Art Unit: 1643

Examiner: A. Harris

DECLARATION BY INVENTORS
UNDER 37 C.F.R. § 1.131

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

We, the undersigned, declare as follows:

1. We are co-inventors of claims 1, 14 and 23, currently pending in the above-referenced application. The claims relate to an isolated 125P5C8 protein comprising the sequence of SEQ ID NO: 2 or a polynucleotide sequence encoding the codons for SEQ ID NO: 2, which is exemplified by the nucleotide sequence of SEQ ID NO:1.

2. The Office rejected claims 1, 14 and 23 as allegedly being anticipated by WO 200270539 A2, which was filed March 5, 2002. This PCT application claims priority to U.S. Application No. 09/799,451, which was filed March 5, 2001, and is now U.S. Patent No. 6,783,989.

A copy of WO 200270539 was submitted in an Information Disclosure Statement provided in this application mailed on April 5, 2001. This document discloses sequence 1397 which is identical to SEQ ID NO: 2 of the present application.

3. We reduced the claimed invention to practice in the United States prior to the date U.S. Patent No. 6,783,989 was filed (March 5, 2001).

4. This reduction to practice is evidenced by a true and accurate copy of an email message sent to various members of the scientific staff by inventor Steve C. Mitchell on January 3, 2001. The email provides the nucleic acid and amino acid sequences of the material encompassed by the claims in the above-referenced patent application. A copy of this email is provided as Exhibit A.

5. The nucleotide sequence disclosed in Exhibit A consists of 2,103 nucleotides and 699 amino acids.

6. Exhibit B shows a comparison of the nucleotide sequence of SEQ ID NO:1 and the nucleotide sequence disclosed in Exhibit A. Every single nucleotide disclosed in SEQ ID NO:1 is present in the nucleotide sequence disclosed in Exhibit A. Accordingly, the email of Exhibit A clearly demonstrates the that nucleotide sequence of SEQ ID NO:1 was in our possession prior to the earliest priority date to which WO 200270539 (the cited art) is entitled to claim.

7. Exhibit C shows a comparison of the amino acid sequence of SEQ ID NO:2 and the amino acid sequence disclosed in Exhibit A. Every single amino acid residue disclosed in SEQ ID NO: 2 is present in the amino acid sequence disclosed in Exhibit A. Accordingly, the email of Exhibit A clearly demonstrates the that amino acid sequence of SEQ ID NO:2 was in our possession prior to the earliest priority date to which WO 200270539 (the cited art) is entitled to claim.

8. In view of the email provided as Exhibit A and the analysis of the sequences disclosed therein and shown in Exhibits B and C, we declare that the invention of the pending claims was reduced to practice in the United States prior to March 5, 2001, the earliest priority date available to the cited document.

We declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date

Executed at

(City/State)

Aya JAKOBOVITS

(City/State)

Daniel E.H. AFAR

(City/State)

Steve Chappell MITCHELL

(City/State)

Pia M. CHALLITA-EID

(City/State)

Arthur B. RAITANO

(City/State)

Mary FARIS

Popp, Shane

From: Mitchell, Steve
Sent: Wednesday, January 03, 2001 1:43 PM
To: Scientists
Subject: 125P5C8 reagents.

Colleagues,

The Company reagent for 125P5C8 (124P1B7/139P3A1) is pasted. It is a PCR based pCR2.1/TA clone(prostate) with three point differences from the Japanese (colon) reported hypothetical sequence. Two point are conserved for translation whereas the third point difference gives an amino acid change near the 3 prime end. This is verified with genomic sequencing.

>125P5C8(124P1B7/139P3A1) pCR2.1 subclone

```
CGATGACCTCGCTGTGGAGAGAAATCCTCTTGGAGTCGCTGCTGGGATGTGTTTCTTGGTCTCTCTACCATGACCTGGGACCGATG
ATCTATTACTTTGCTTTGCAAAACACTAGAATCACTAGGCTTGAAGGTTTAGTATAGCATTCTTTCTCCAATATTCCTAACAATTACT
CCTTTCTGGAATTTGGTTAACAAGAAGTGGATGCTAAACCTGCTGAGGATAATCACTATTGGCAGCATAGCCTCCTTCCAGGCTCCA
AATGCCAAACTTCGACTGATGGTCTTGGGCTTGGGGTGTCTTCTCACTGATAGTGCAGCTGTGACTTGGTGGTCGGGAAGTCAT
TTGCAAAGGTACCTCAGAAATTTGGGATTCATTTTAGGACAGATTGTTCTTGTGTTCTACGCATATGGTATACCTCACTAAACCCAAT
CTGGAGTTATCAGATGTCCAACAAGTATGATACCTAGGACAGCTTGGGCTTAGACCTTAGACCTTAGACCTTAGACCTTAGACCTTAGACCT
TAAACCTGAAGAAAAGAAGACTGGTGAGGTAGCCACGGGGATGGCTCTAGACCTTAGACCTTAGACCTTAGACCTTAGACCTTAGACCT
AGCCTTGTGTTTCTCACCCTAGGCTTGGGATTTTGGAGAAGTCTCTTGTTCAGATGGGCAAGTGAAGTGGCATCCACATCCAGGGCC
AGATCCTAACCCTTTGGAGGTGCACTACTGCTGTGCTTGGCAAGTGGATTGATGCTTCCATCTTGTGTTGTTGTTGTTGTTGTTGTTGTT
TTTGATCTGGTGGGTTTACAGGAACAGCTTCACTGCGGGCTCCTTTACCTGCACACATGGGCAAGTGGCTGTGTCTGGCTGTGTCT
TCGCCATCTTTACTGCATCCATGTGGGCCCCAACACTTGGACACCTTATTAACCTAGGACAAACCTGGGAAACCATGACCATTTG
CCATGATATTTTATCTTCTAGAAATATTTTCTGTGCTGGTGCACAGCTTTTAACTAGGACAAACCTGGGAAACCATGACCATTTG
ATCAGATGTGCTTTTGGGGAACATGATGTTAATTATCGGGCTGAATATGCTATTTGGTCTAAGAAAAACCTTGAAGTGGTCTACGCTAGAGAAAG
ACAAAAACAGTTCTAAAGTGTCTTTTACAGAAAGAGTGAAAAATACATGAAACTTTTCTGTGGCTGCTTGTGGTGTGGGATTGTTGG
GATTAGGACTACGGCATAAAGCCTATGAGAGAAAACTGGGCAAGTGGCACCACCAAGAGGTCTCTGCTGCCATCTGGCCTTTG
AGGTTTGGATATGACAATGAAGGGTGGTCTAGTCTAGAAAGATCAGCTCACTGCTCAATGAAACAGGTGCAGATTTTATAACAATT
TTGGAGAGTGTGCTTCTAAGCCCTATATGGGGAACATGACTTAACCATGTGGCTAGGGGAAAAGTTGGGTTTCTATACAGACTTT
GTCCCAAGCACAAGGTATCACACTTGGGGGATTATGGCTTTGTCAAGATACCCAATTGTGAAATCTGAGCATCACCTTCTCCGTCA
CAGAGGGGCGAGATCGCACCAGCCATCACATTGACCGTTAACATTTCCGGCAAGCTGGTGGATTGTTGCTGTGACACACTTTGGGAA
ATATCACTTTCAGCACTGGCTCCAGAGATTATCTACAGCTCACTGAACATGGCAATGTGAAGGATATCGACAGCACTGATCATGA
AGATGGTGTGAATACATTATGTATCGAGGGCTGATCAGGTTGGGTTATGCAAGAATCTCCCATGCTGAAGTGAAGTGAAGTGAAGT
CAGATGGCAAAATTTAGGATCCCTGATGACCCCACTAATTATAGAGACAACCAGAAAGTGGTCATAGACCACAGAGAAGTTTCTGA
AAAATTCATTTAATCCAGATTGATGATCTACAAAGAAGGACACAATTATGAAAAACAACCATCATTTTCATATGAATACTCCCAAT
CTTTTTATGAAC
```

125P5C8(124P1B7/139P3A1) pCR2.1 subclone

```
ITSLWREILLESLLGCYSWSLYHDLGPMIYFPLQLTLELTGLEGSIAFLSPHLLTTPFWKLVNKKWMLTLRLITIGSIASFQAPNAKLRLM
LALGVSSSLIVQAVTWVSGSHLQRYLRWGFILGQNLVYLRWYTSLNPIWSYQMSNKKVILTLAIAITLDRIGTDGDCSKPEEKKTGEVA
SMASRPNNWLLAGAAFGSLVFLTHWVFGEVSLVSRWAVSGHIFHPGDPNPFEGGAVLLCLASGLMLPSCWFRGTGLWVWVTGTASAA
LLYUHTWAAVSGCVFAIFTASMWPTLGLHINSNTNPGKMTIAMIFYLLEIFFCAWCTAFKFVPGGVYARERSDVLGLTMMUIGUNML
PKQNLDDLQTONSSKVLFRKSEKYMQLFLWLLVGVGLLGLRLHKAVERKLGKVAPTKEVSAANWPFREFGYDNEGWSSSLERSAHLL
ETGADFITLES DASKPYMGNNDLTMWLGEKLGFTYDFGPSTRYHTWGMALSRYPYKSEHLLPSPEGEIAPATLTVNISGKLVDFVY
FGNHEDDLDRKLQAIYVSKLLKSSSNQVIFLGYTSAPGSRDYLQLTEHGNVKDIDSTDHWRWCEYIMYRGLRGLYARISHAELSDEI
IAKFRIPDDPTNYRDNQKVVDHREVSEKHFNPRFGSYKEGHYNNHIFHMNTPKYFL
```

ve Chappell Mitchell
Associate Scientist
Genesys
1 Colorado Avenue
La Jolla, CA 92037
(310)820-8029 x281
(310)820-8489
smitchell@urogenesys.com
www.urogenesys.com

Exhibit B**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

atgacctcgc tgtggagaga aatcctcttg gagtcgctgc tgggatgtgt ttcttgggtct SID#1
|||||
cg atgacctcgc tgtggagaga aatcctcttg gagtcgctgc tgggatgtgt ttcttgggtct Email

ctctaccatg acctgggacc gatgatctat tacttttcctt tgcaaacact agaactcact SID#1
|||||
ctctaccatg acctgggacc gatgatctat tacttttcctt tgcaaacact agaactcact Email

gggcttgaag gtttttagtat agcatttctt tctccaatat tcctaacaat tactcctttc SID#1
|||||
gggcttgaag gtttttagtat agcatttctt tctccaatat tcctaacaat tactcctttc Email

tggaaattgg ttaacaagaa gtggatgcta accctgctga ggataatcac tattggcagc SID#1
|||||
tggaaattgg ttaacaagaa gtggatgcta accctgctga ggataatcac tattggcagc Email

atagcctcct tccaggctcc aaatgccaaa cttcgactga tggttcttgc gcttgggggtg SID#1
|||||
atagcctcct tccaggctcc aaatgccaaa cttcgactga tggttcttgc gcttgggggtg Email

tcttcctcac tgatagtga agctgtgact tggtggtcgg gaagtcattt gcaaaggtag SID#1
|||||
tcttcctcac tgatagtga agctgtgact tggtggtcgg gaagtcattt gcaaaggtag Email

ctcagaattt ggggattcat tttaggacag attgttcttg ttgttctacg catatggtat SID#1
|||||
ctcagaattt ggggattcat tttaggacag attgttcttg ttgttctacg catatggtat Email

acttcactaa acccaatctg gagttatcag atgtccaaca aagtgatact gacattaagt SID#1
|||||
acttcactaa acccaatctg gagttatcag atgtccaaca aagtgatact gacattaagt Email

gccatagcca cacttgatcg tattggcaca gatggtgact gcagtaaacc tgaagaaaag SID#1
|||||
gccatagcca cacttgatcg tattggcaca gatggtgact gcagtaaacc tgaagaaaag Email

aagactggtg aggtagccac ggggatggcc tctagacca actggctgct ggcaggggct SID#1
|||||
aagactggtg aggtagccac ggggatggcc tctagacca actggctgct ggcaggggct Email

gcttttggtg gccttggtgt cctcaccac tgggtttttg gagaagtctc tcttgtttcc SID#1
|||||
gcttttggtg gccttggtgt cctcaccac tgggtttttg gagaagtctc tcttgtttcc Email

Exhibit B

A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email

agatgggcag tgagtgggca tccacatcca gggccagatc ctaacccatt tggaggtgca SID#1
|||||
agatgggcag tgagtgggca tccacatcca gggccagatc ctaacccatt tggaggtgca Email

gtactgctgt gcttggcaag tggattgatg cttccatctt gtttgtggtt tcgtggtact SID#1
|||||
gtactgctgt gcttggcaag tggattgatg cttccatctt gtttgtggtt tcgtggtact Email

ggtttgatct ggtgggttac aggaacagct tcagctgcgg ggctccttta cctgcacaca SID#1
|||||
ggtttgatct ggtgggttac aggaacagct tcagctgcgg ggctccttta cctgcacaca Email

tgggcagctg ctgtgtctgg ctgtgtcttc gccatcttta ctgcatccat gtggcccca SID#1
|||||
tgggcagctg ctgtgtctgg ctgtgtcttc gccatcttta ctgcatccat gtggcccca Email

acacttgac accttattaa ctcagggaca aaccctggga aaaccatgac cattgccatg SID#1
|||||
acacttgac accttattaa ctcagggaca aaccctggga aaaccatgac cattgccatg Email

atattttatc ttctagaaat atttttctgt gcctggtgca cagcttttaa gtttgtccca SID#1
|||||
atattttatc ttctagaaat atttttctgt gcctggtgca cagcttttaa gtttgtccca Email

ggaggtgtct acgctagaga aagatcagat gtgcttttgg ggacaatgat gttaattatc SID#1
|||||
ggaggtgtct acgctagaga aagatcagat gtgcttttgg ggacaatgat gttaattatc Email

gggctgaata tgctatttgg tcctaagaaa aaccttgact tgcttcttca aacaaaaaac SID#1
|||||
gggctgaata tgctatttgg tcctaagaaa aaccttgact tgcttcttca aacaaaaaac Email

agttctaaag tgcttttcag aaagagtga aaatacatga aactttttct gtggctgctt SID#1
|||||
agttctaaag tgcttttcag aaagagtga aaatacatga aactttttct gtggctgctt Email

gttggtgtgg gattgttggg attaggacta cggcataaag cctatgagag aaaactgggc SID#1
|||||
gttggtgtgg gattgttggg attaggacta cggcataaag cctatgagag aaaactgggc

Exhibit B**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-------|
| aaagtggcac | caaccaaaga | ggtctctgct | gccatctggc | ctttcaggtt | tggatatgac | SID#1 |
| | | | | | | |
| aaagtggcac | caaccaaaga | ggtctctgct | gccatctggc | ctttcaggtt | tggatatgac | Email |

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-------|
| aatgaagggt | ggtctagtct | agaaagatca | gctcacctgc | tcaatgaaac | aggtgcagat | SID#1 |
| | | | | | | |
| aatgaagggt | ggtctagtct | agaaagatca | gctcacctgc | tcaatgaaac | aggtgcagat | Email |

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-------|
| ttcataacaa | ttttggagag | tgatgcttct | aagccctata | tggggaacaa | tgacttaacc | SID#1 |
| | | | | | | |
| ttcataacaa | ttttggagag | tgatgcttct | aagccctata | tggggaacaa | tgacttaacc | Email |

| | | | | | | |
|------------|------------|------------|------------|------------|-----------|-------|
| atgtggctag | gggaaaagtt | gggtttctat | acagactttg | gtccaagcac | aaggatcac | SID#1 |
| | | | | | | |
| atgtggctag | gggaaaagtt | gggtttctat | acagactttg | gtccaagcac | aaggatcac | Email |

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-------|
| acttggggga | ttatggcttt | gtcaagatac | ccaattgtga | aatctgagca | tcaccttctt | SID#1 |
| | | | | | | |
| acttggggga | ttatggcttt | gtcaagatac | ccaattgtga | aatctgagca | tcaccttctt | Email |

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-------|
| ccgtcaccag | agggcgagat | cgcaccagcc | atcacattga | ccgttaacat | ttcgggcaag | SID#1 |
| | | | | | | |
| ccgtcaccag | agggcgagat | cgcaccagcc | atcacattga | ccgttaacat | ttcgggcaag | Email |

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-------|
| ctggtggatt | ttgtcgtgac | acactttggg | aaccacgaag | atgacctcga | caggaaactg | SID#1 |
| | | | | | | |
| ctggtggatt | ttgtcgtgac | acactttggg | aaccacgaag | atgacctcga | caggaaactg | Email |

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-------|
| caggctattg | ctgtttcaaa | actactgaaa | agtagctcta | atcaagtgat | atttctggga | SID#1 |
| | | | | | | |
| caggctattg | ctgtttcaaa | actactgaaa | agtagctcta | atcaagtgat | atttctggga | Email |

| | | | | | | |
|------------|------------|------------|------------|-------------|------------|-------|
| tatatcactt | cagcacctgg | ctccagagat | tatctacagc | tcaactgaaca | tggcaatgtg | SID#1 |
| | | | | | | |
| tatatcactt | cagcacctgg | ctccagagat | tatctacagc | tcaactgaaca | tggcaatgtg | Email |

| | | | | | | |
|------------|------------|------------|-------------|------------|------------|-------|
| aaggatatcg | acagcactga | tcatgacaga | tgggtgtgaat | acattatgta | tcgagggctg | SID#1 |
| | | | | | | |
| aaggatatcg | acagcactga | tcatgacaga | tgggtgtgaat | acattatgta | tcgagggctg | Email |

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-------|
| atcaggttgg | gttatgcaag | aatctcccat | gctgaactga | gtgattcaga | aattcagatg | SID#1 |
| | | | | | | |
| atcaggttgg | gttatgcaag | aatctcccat | gctgaactga | gtgattcaga | aattcagatg | |

Exhibit B**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

| | | | | | | |
|------------|------------|-----------|------------|------------|------------|-------|
| gcaaaattta | ggatccctga | tgacccact | aattatagag | acaaccagaa | agtgggcata | SID#1 |
| | | | | | | |
| gcaaaattta | ggatccctga | tgacccact | aattatagag | acaaccagaa | agtgggcata | Email |

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-------|
| gaccacagag | aagtttctga | gaaaattcat | tttaatccca | gatttggatc | ctacaaagaa | SID#1 |
| | | | | | | |
| gaccacagag | aagtttctga | gaaaattcat | tttaatccca | gatttggatc | ctacaaagaa | Email |

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-------|
| ggacacaatt | atgaaaacaa | ccatcatttt | catatgaata | ctcccaaata | ctttttatga | SID#1 |
| | | | | | | |
| ggacacaatt | atgaaaacaa | ccatcatttt | catatgaata | ctcccaaata | ctttttatga | Email |

| | |
|-----|-------|
| aac | SID#1 |
| | |
| aac | Email |

Exhibit C**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Met Thr Ser Leu Trp Arg Glu Ile Leu Leu Glu Ser Leu Leu Gly (SID #2)
 | | | | | | | | | | | | | |
 Met Thr Ser Leu Trp Arg Glu Ile Leu Leu Glu Ser Leu Leu Gly (Email)

Cys Val Ser Trp Ser Leu Tyr His Asp Leu Gly Pro Met Ile Tyr Tyr (SID #2)
 | | | | | | | | | | | | | |
 Cys Val Ser Trp Ser Leu Tyr His Asp Leu Gly Pro Met Ile Tyr Tyr (Email)

Phe Pro Leu Gln Thr Leu Glu Leu Thr Gly Leu Glu Gly Phe Ser Ile (SID #2)
 | | | | | | | | | | | | | |
 Phe Pro Leu Gln Thr Leu Glu Leu Thr Gly Leu Glu Gly Phe Ser Ile (Email)

Ala Phe Leu Ser Pro Ile Phe Leu Thr Ile Thr Pro Phe Trp Lys Leu (SID #2)
 | | | | | | | | | | | | | |
 Ala Phe Leu Ser Pro Ile Phe Leu Thr Ile Trp Pro Phe Trp Lys Leu (Email)

Val Asn Lys Lys Trp Met Leu Thr Leu Leu Arg Ile Ile Thr Ile Gly (SID #2)
 | | | | | | | | | | | | | |
 Val Asn Lys Lys Trp Met Leu Thr Leu Leu Arg Ile Ile Thr Ile Gly (Email)

Ser Ile Ala Ser Phe Gln Ala Pro Asn Ala Lys Leu Arg Leu Met Val (SID #2)
 | | | | | | | | | | | | | |
 Ser Ile Ala Ser Phe Gln Ala Pro Asn Ala Lys Leu Arg Leu Met Val (Email)

Leu Ala Leu Gly Val Ser Ser Ser Leu Ile Val Gln Ala Val Thr Trp (SID #2)
 | | | | | | | | | | | | | |
 Leu Ala Leu Gly Val Ser Ser Ser Leu Ile Val Gln Ala Val Thr Trp (Email)

Trp Ser Gly Ser His Leu Gln Arg Tyr Leu Arg Ile Trp Gly Phe Ile (SID #2)
 | | | | | | | | | | | | | |
 Trp Ser Gly Ser His Leu Gln Arg Tyr Leu Arg Ile Trp Gly Phe Ile (Email)

Leu Gly Gln Ile Val Leu Val Val Leu Arg Ile Trp Tyr Thr Ser Leu (SID #2)
 | | | | | | | | | | | | | |
 Leu Gly Gln Ile Val Leu Val Val Leu Arg Ile Trp Tyr Thr Ser Leu (Email)

Asn Pro Ile Trp Ser Tyr Gln Met Ser Asn Lys Val Ile Leu Thr Leu (SID #2)
 | | | | | | | | | | | | | |
 Asn Pro Ile Trp Ser Tyr Gln Met Ser Asn Lys Val Ile Leu Thr Leu (Email)

Ser Ala Ile Ala Thr Leu Asp Arg Ile Gly Thr Asp Gly Asp Cys Ser (SID #2)
 | | | | | | | | | | | | | |
 Ser Ala Ile Ala Thr Leu Asp Arg Ile Gly Thr Asp Gly Asp Cys Ser (Email)

Exhibit C**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Lys Pro Glu Glu Lys Lys Thr Gly Glu Val Ala Thr Gly Met Ala Ser (SID #2)
 | | | | | | | | | | | | | | |
 Lys Pro Glu Glu Lys Lys Thr Gly Glu Val Ala Thr Gly Met Ala Ser (Email)

Arg Pro Asn Trp Leu Leu Ala Gly Ala Ala Phe Gly Ser Leu Val Phe (SID #2)
 | | | | | | | | | | | | | | |
 Arg Pro Asn Trp Leu Leu Ala Gly Ala Ala Phe Gly Ser Leu Val Phe (Email)

Leu Thr His Trp Val Phe Gly Glu Val Ser Leu Val Ser Arg Trp Ala (SID #2)
 | | | | | | | | | | | | | | |
 Leu Thr His Trp Val Phe Gly Glu Val Ser Leu Val Ser Arg Trp Ala (Email)

Val Ser Gly His Pro His Pro Gly Pro Asp Pro Asn Pro Phe Gly Gly (SID #2)
 | | | | | | | | | | | | | | |
 Val Ser Gly His Pro His Pro Gly Pro Asp Pro Asn Pro Phe Gly Gly (Email)

Ala Val Leu Leu Cys Leu Ala Ser Gly Leu Met Leu Pro Ser Cys Leu (SID #2)
 | | | | | | | | | | | | | | |
 Ala Val Leu Leu Cys Leu Ala Ser Gly Leu Met Leu Pro Ser Cys Leu (Email)

Trp Phe Arg Gly Thr Gly Leu Ile Trp Trp Val Thr Gly Thr Ala Ser (SID #2)
 | | | | | | | | | | | | | | |
 Trp Phe Arg Gly Thr Gly Leu Ile Trp Trp Val Thr Gly Thr Ala Ser (Email)

Ala Ala Gly Leu Leu Tyr Leu His Thr Trp Ala Ala Ala Val Ser Gly (SID #2)
 | | | | | | | | | | | | | | |
 Ala Ala Gly Leu Leu Tyr Leu His Thr Trp Ala Ala Ala Val Ser Gly (Email)

Cys Val Phe Ala Ile Phe Thr Ala Ser Met Trp Pro Gln Thr Leu Gly (SID #2)
 | | | | | | | | | | | | | | |
 Cys Val Phe Ala Ile Phe Thr Ala Ser Met Trp Pro Gln Thr Leu Gly (Email)

His Leu Ile Asn Ser Gly Thr Asn Pro Gly Lys Thr Met Thr Ile Ala (SID #2)
 | | | | | | | | | | | | | | |
 His Leu Ile Asn Ser Gly Thr Asn Pro Gly Lys Thr Met Thr Ile Ala (Email)

Met Ile Phe Tyr Leu Leu Glu Ile Phe Phe Cys Ala Trp Cys Thr Ala (SID #2)
 | | | | | | | | | | | | | | |
 Met Ile Phe Tyr Leu Leu Glu Ile Phe Phe Cys Ala Trp Cys Thr Ala (Email)

Phe Lys Phe Val Pro Gly Gly Val Tyr Ala Arg Glu Arg Ser Asp Val (SID #2)
 | | | | | | | | | | | | | | |
 Phe Lys Phe Val Pro Gly Gly Val Tyr Ala Arg Glu Arg Ser Asp Val (Email)

Exhibit C**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Leu Leu Gly Thr Met Met Leu Ile Ile Gly Leu Asn Met Leu Phe Gly (SID #2)
 | | | | | | | | | | | | | | |
 Leu Leu Gly Thr Met Met Leu Ile Ile Gly Leu Asn Met Leu Phe Gly (Email)

Pro Lys Lys Asn Leu Asp Leu Leu Leu Gln Thr Lys Asn Ser Ser (SID #2)
 | | | | | | | | | | | | | | |
 Pro Lys Lys Asn Leu Asp Leu Leu Leu Gln Thr Lys Asn Ser Ser (Email)

Lys Val Leu Phe Arg Lys Ser Glu Lys Tyr Met Lys Leu Phe Leu Trp (SID #2)
 | | | | | | | | | | | | | | |
 Lys Val Leu Phe Arg Lys Ser Glu Lys Tyr Met Lys Leu Phe Leu Trp (Email)

Leu Leu Val Gly Val Gly Leu Leu Gly Leu Gly Leu Arg His Lys Ala (SID #2)
 | | | | | | | | | | | | | | |
 Leu Leu Val Gly Val Gly Leu Leu Gly Leu Gly Leu Arg His Lys Ala (Email)

Tyr Glu Arg Lys Leu Gly Lys Val Ala Pro Thr Lys Glu Val Ser Ala Ala (SID #2)
 | | | | | | | | | | | | | | |
 Tyr Glu Arg Lys Leu Gly Lys Val Ala Pro Thr Lys Glu Val Ser Ala Ala (Email)

Ile Trp Pro Phe Arg Phe Gly Tyr Asp Asn Glu Gly Trp Ser Ser (SID #2)
 | | | | | | | | | | | | | | |
 Ile Trp Pro Phe Arg Phe Gly Tyr Asp Asn Glu Gly Trp Ser Ser (Email)

Leu Glu Arg Ser Ala His Leu Leu Asn Glu Thr Gly Ala Asp Phe Ile (SID #2)
 | | | | | | | | | | | | | | |
 Leu Glu Arg Ser Ala His Leu Leu Asn Glu Thr Gly Ala Asp Phe Ile (Email)

Thr Ile Leu Glu Ser Asp Ala Ser Lys Pro Tyr Met Gly Asn Asn Asp (SID #2)
 | | | | | | | | | | | | | | |
 Thr Ile Leu Glu Ser Asp Ala Ser Lys Pro Tyr Met Gly Asn Asn Asp (Email)

Leu Thr Met Trp Leu Gly Glu Lys Leu Gly Phe Tyr Thr Asp Phe Gly (SID #2)
 | | | | | | | | | | | | | | |
 Leu Thr Met Trp Leu Gly Glu Lys Leu Gly Phe Tyr Thr Asp Phe Gly (Email)

Pro Ser Thr Arg Tyr His Thr Trp Gly Ile Met Ala Leu Ser Arg Tyr (SID #2)
 | | | | | | | | | | | | | | |
 Pro Ser Thr Arg Tyr His Thr Trp Gly Ile Met Ala Leu Ser Arg Tyr (Email)

Pro Ile Val Lys Ser Glu His His Leu Leu Pro Ser Pro Glu Gly Glu (SID #2)
 | | | | | | | | | | | | | | |
 Pro Ile Val Lys Ser Glu His His Leu Leu Pro Ser Pro Glu Gly Glu (Email)

Exhibit C**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Ile Ala Pro Ala Ile Thr Leu Thr Val Asn Ile Ser Gly Lys Leu Val (SID #2)
 | | | | | | | | | | | | | | |
 Ile Ala Pro Ala Ile Thr Leu Thr Val Asn Ile Ser Gly Lys Leu Val (Email)

Asp Phe Val Val Thr His Phe Gly Asn His Glu Asp Asp Leu Asp Arg (SID #2)
 | | | | | | | | | | | | | | |
 Asp Phe Val Val Thr His Phe Gly Asn His Glu Asp Asp Leu Asp Arg (Email)

Lys Leu Gln Ala Ile Ala Val Ser Lys Leu Leu Lys Ser Ser Ser Asn (SID #2)
 | | | | | | | | | | | | | | |
 Lys Leu Gln Ala Ile Ala Val Ser Lys Leu Leu Lys Ser Ser Ser Asn (Email)

Gln Val Ile Phe Leu Gly Tyr Ile Thr Ser Ala Pro Gly Ser Arg Asp (SID #2)
 | | | | | | | | | | | | | | |
 Gln Val Ile Phe Leu Gly Tyr Ile Thr Ser Ala Pro Gly Ser Arg Asp

Tyr Leu Gln Leu Thr Glu His Gly Asn Val Lys Asp Ile Asp Ser Thr (SID #2)
 | | | | | | | | | | | | | | |
 Tyr Leu Gln Leu Thr Glu His Gly Asn Val Lys Asp Ile Asp Ser Thr (Email)

Asp His Asp Arg Trp Cys Glu Tyr Ile Met Tyr Arg Gly Leu Ile Arg (SID #2)
 | | | | | | | | | | | | | | |
 Asp His Asp Arg Trp Cys Glu Tyr Ile Met Tyr Arg Gly Leu Ile Arg (Email)

Leu Gly Tyr Ala Arg Ile Ser His Ala Glu Leu Ser Asp Ser Glu Ile (SID #2)
 | | | | | | | | | | | | | | |
 Leu Gly Tyr Ala Arg Ile Ser His Ala Glu Leu Ser Asp Ser Glu Ile (Email)

Gln Met Ala Lys Phe Arg Ile Pro Asp Asp Pro Thr Asn Tyr Arg Asp (SID #2)
 | | | | | | | | | | | | | | |
 Gln Met Ala Lys Phe Arg Ile Pro Asp Asp Pro Thr Asn Tyr Arg Asp (Email)

Asn Gln Lys Val Val Ile Asp His Arg Glu Val Ser Glu Lys Ile His (SID #2)
 | | | | | | | | | | | | | | |
 Asn Gln Lys Val Val Ile Asp His Arg Glu Val Ser Glu Lys Ile His (SID #2)

Phe Asn Pro Arg Phe Gly Ser Tyr Lys Glu Gly His Asn Tyr Glu Asn (SID #2)
 | | | | | | | | | | | | | | |
 Phe Asn Pro Arg Phe Gly Ser Tyr Lys Glu Gly His Asn Tyr Glu Asn (Email)

Asn His His Phe His Met Asn Thr Pro Lys Tyr Phe Leu (SID #2)
 | | | | | | | | | | | | | | |
 Asn His His Phe His Met Asn Thr Pro Lys Tyr Phe Leu (Email)

COPY

Conte



DHL USA Home

[Return to DHLUSA](#)

Track results detail

Tracking results detail for 29686554752

Tracking summary

Current Status ☒ **Shipment delivered.** [View Signature](#)

Delivered on 1/30/2006 10:32 am

Delivered to Residence Door

Signed for by **LD FD -601 LINDEN PL** [What is this?](#)

Tracking history

| Date and Time | Status | Location |
|--------------------|--------------------------|-------------------|
| 1/30/2006 10:32 am | Shipment delivered. | Franklin Park, IL |
| 1/28/2006 7:59 am | Arrived at DHL facility. | Franklin Park, IL |
| 1/27/2006 5:15 pm | Departing origin. | Santa Monica, CA |
| 4:09 pm | Picked Up by DHL. | Shipper's Door |

| | | |
|---|---|--|
| Ship From: AGENSYS Santa Monica, CA 90404 United States | Ship To: STEVE CHAPPELL MITCHELL Evanston, IL 60202 United States | Shipment Information: Ship date: 1/27/2006 Pieces: 1 Total weight: 1 lb Ship Type: Letter Expre Shipment Reference: 61 INTELLECT PROP. Service: Next Day Special Service: Description: |
| Attention: AGENSYS | Attention: STEVE CHAPPELL MITCHELL | |

Tracking detail provided by DHL: 2/14/2006, 8:09:03 am pt.

[Track new](#)

You are authorized to use DHL tracking systems solely to track shipments tendered by or for you to [use of DHL tracking systems and information is strictly prohibited.

New to DHL?

Registration is quick and easy. And as a registered user, you'll have access to services and tools to help you ship your packages easily and efficiently.

[Register Now](#)

Questions?

We're here to help!

[Contact DHL](#)

03 March 2006

Sent via Worldwide Express / DHL

Mr. Steven Chappell Mitchell
601 Linden Place
#311 loft
Evanston, IL 60201

RE: U.S. Patent Application:
Title: 125P5C8: A TISSUE SPECIFIC PROTEIN HIGHLY EXPRESSED IN
VARIOUS CANCERS
Serial No.: 09/809,638
Our Ref.: 51158-20035.00

Dear Steve:

Further to our previous letter dated 27-January-2006, please find enclosed a Declaration under 37 C.F.R. §1.131 for the above-referenced patent application for which you are listed as an inventor. The need for a §1.131 Declaration came about when; during prosecution of the above-referenced case, the Patent Examiner cited WO/200270539 as allegedly anticipating our claims.

37 C.F.R. 1.131(a) states in pertinent part:

“When any claim of an application is rejected, the inventor of the subject matter of the rejected claim may submit an appropriate oath or declaration to establish invention of the subject matter of the rejected claim prior to the effective date of the reference or activity on which the rejection is based.”

Accordingly, please find enclosed a copy of the 1.31 Declaration for your execution on the above-referenced matter, a copy of a document demonstrating reduction to practice prior to the WO/200270539 document which has an effective date of 05 March 2001.

Please review the enclosed documents and sign and date the enclosed §1.131 Declaration and return it to us as soon as possible. I have enclosed a return DHL envelope for your convenience.

If you have any questions feel free to contact me at 310.820.8029 ext. 205.

With regards,


Shane M. Popp J.D., LL.M.
Manager, Legal

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mary FARIS, et al.

Application No.: 09/809,638

Filed: March 14, 2001

For: 125P5C8: A TISSUE SPECIFIC PROTEIN
HIGHLY EXPRESSED IN VARIOUS
CANCERS

Art Unit: 1643

Examiner: A. Harris

DECLARATION BY INVENTORS

UNDER 37 C.F.R. § 1.131

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

We, the undersigned, declare as follows:

1. We are co-inventors of claims 1, 14 and 23, currently pending in the above-referenced application. The claims relate to an isolated 125P5C8 protein comprising the sequence of SEQ ID NO: 2 or a polynucleotide sequence encoding the codons for SEQ ID NO: 2, which is exemplified by the nucleotide sequence of SEQ ID NO:1.

2. The Office rejected claims 1, 14 and 23 as allegedly being anticipated by WO 200270539 A2, which was filed March 5, 2002. This PCT application claims priority to U.S. Application No. 09/799,451, which was filed March 5, 2001, and is now U.S. Patent No. 6,783,989.

A copy of WO 200270539 was submitted in an Information Disclosure Statement provided in this application mailed on April 5, 2001. This document discloses sequence 1397 which is identical to SEQ ID NO: 2 of the present application.

3. We reduced the claimed invention to practice in the United States prior to the date U.S. Patent No. 6,783,989 was filed (March 5, 2001).

4. This reduction to practice is evidenced by a true and accurate copy of an email message sent to various members of the scientific staff by inventor Steve C. Mitchell on January 3, 2001. The email provides the nucleic acid and amino acid sequences of the material encompassed by the claims in the above-referenced patent application. A copy of this email is provided as Exhibit A.

5. The nucleotide sequence disclosed in Exhibit A consists of 2,103 nucleotides and 699 amino acids.

6. Exhibit B shows a comparison of the nucleotide sequence of SEQ ID NO:1 and the nucleotide sequence disclosed in Exhibit A. Every single nucleotide disclosed in SEQ ID NO:1 is present in the nucleotide sequence disclosed in Exhibit A. Accordingly, the email of Exhibit A clearly demonstrates the that nucleotide sequence of SEQ ID NO:1 was in our possession prior to the earliest priority date to which WO 200270539 (the cited art) is entitled to claim.

7. Exhibit C shows a comparison of the amino acid sequence of SEQ ID NO:2 and the amino acid sequence disclosed in Exhibit A. Every single amino acid residue disclosed in SEQ ID NO: 2 is present in the amino acid sequence disclosed in Exhibit A. Accordingly, the email of Exhibit A clearly demonstrates the that amino acid sequence of SEQ ID NO:2 was in our possession prior to the earliest priority date to which WO 200270539 (the cited art) is entitled to claim.

8. In view of the email provided as Exhibit A and the analysis of the sequences disclosed therein and shown in Exhibits B and C, we declare that the invention of the pending claims was reduced to practice in the United States prior to March 5, 2001, the earliest priority date available to the cited document.

We declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date

Executed at

(City/State)

Aya JAKOBOVITS

(City/State)

Daniel E.H. AFAR

(City/State)

Steve Chappell MITCHELL

(City/State)

Pia M. CHALLITA-EID

(City/State)

Arthur B. RAITANO

(City/State)

Mary FARIS

From: Mitchell, Steve
 Sent: Wednesday, January 03, 2001 1:43 PM
 To: Scientists
 Subject: 125P5C8 reagents.

Colleagues,

The Company reagent for 125P5C8 (124P1B7/139P3A1) is posted. It is a PCR based pCR2.1/TA clone (prostate) with three point differences from the Japanese (colon) reported hypothetical sequence. Two point are conserved for translation whereas the third point difference gives an amino acid change near the 3 prime end. This is verified with genomic sequencing.

>125P5C8(124P1B7/139P3A1) pCR2.1 subclone

CGATGACCTCGCTGTGGAGAGAAATCCTCTTGGAGTCTGCTGCTGGGATGTGTTTCTTGGTCTCTCTACCATGACCTGGGACCGATG
 ATCTATTACTTTCCTTTGCAAAACACTAGAATCACTGAGGCTTGAAGGTTTAGTATAGCATTCTTTCTCCAATATTCCTAACAATTAGT
 CCTTTCTGGAATTTGGTTAACAAGAAGTGGATGCTAAACCTGCTGAGGATAATCACTATTGGCAGCATAGCCTCCTTCCAGGCTCCA
 AATGCCAAACTTCGACTGATGGTCTTTCGCGCTTGGGGTGTCTTCTCACTGATAGTGAAGCTGTGACTTGGTGGTGGGAAATCAT
 TTGCAAAAGGTACCTCAGAAATTTGGGGATTCAATTTAGGACAGATTGTTCTTGTGTTCTACGCATATGGTATACTTCACTAAACCCAAT
 CTGGAGTTATCAGATTGCAACAAAGTGATACTGACATTAAGTGCCATAGCCACACTTGATCGTATTGGCAGAGATGGTGAATGCGAG
 TAAACCTGAAGAAAAGAAGACTGGTGAGGTAGCCACGGGGATGGCCTAGACCCAAGTGGCTGCTGGCAGGGGGCTGCTTTTGGT
 AGCCTTGTGTTTCTCACCCTAGGGTTTTTGGAGAAGTCTCTTGTGTTCCAGATGGGCAAGTGAATGAGTGGCATCCACATCCAGGGCC
 AGATCCTAACCCATTTGGAGGTGCACTACTGCTGTGCTTGGCAAGTGGATTGATGCTTCCATCTTGTGTTGGTTCGTGGTACTGG
 TTGATCTGGTGGGTTACAGGAACAGCTTCAGCTGCGGGGCTCCTTACCTGCACACATGGGCAGCTGCTGTGTCTGGCTGTGTCT
 TCGCCATCTTTACTGCATCCATGTGGCCCCAACACTTGGACACCTTATTAAGTTCAGGGACAAACCTGGGAAAACCATGACCATTTG
 CCATGATATTTATCTTCTAGAAATATTTTCTGTGCCTGGTGACAGCTTTTAAAGTTTGTCCAGGAGGTGTCTACGCTAGAGAAAG
 ATCAGATGTGCTTTTGGGGAATGATGTTAATTATCGGGCTGAATATGCTATTTGGTCTAAGAAAAACCTTGACTTGTCTTCTCAA
 ACAAAAAACAGTTCTAAAGTGCTTTTCAAGAAAGAGTGAAAAATACATGAACTTTTCTGTGGCTGCTTGTGGTGTGGGATTGTGG
 GATTAGGACTACGGCATAAAGCCTATGAGAGAAAACTGGGCAAGTGGCAACCAAGAGGTCTCTGCTGCCATCTGGCCTTTC
 AGGTTTGGATATGACAATGAAGGGTGGTCTAGTCTAGAAAGATCAGCTCAGCTGCTCAATGAAACAGGTGCAGATTTCAACAATT
 TTGGAGAGTGATGCTTCTAAGCCTATATGGGGAACAACTGACTTAACCATGTGGCTAGGGGAAAAGTTGGGTTTCTATACAGACTTT
 GGTCCAAGCACAAGGTATCACACTTGGGGGATTATGGCTTTGTCAAGATACCCAATTGTGAAATCTGAGCATCACCTTCTCCGTCA
 CCAGAGGGGAGATCGCACCAGCCATCACATTGACCGTTAACATTTCGGGCAAGCTGGTGGATTTTGTCTGTGACACACTTTGGGAA
 CCAGGAAGATGACCTCGACAGGAACTGCAGGCTATTGCTGTTTCAAACTACTGAAAAGTAGCTCTAATCAAGTGATATTTCTGGG
 ATATACCTTTCAGCACTGGCTCCAGAGATTATCTACAGCTCACTGAACATGGCAATGTGAAGGATATCGACAGCACTGATCATGA
 CAGATGGTGTGAATACATTATGATCGAGGGCTGATCAGGTTGGGTTATGCAAGAAATCTCCCATGCTGAAGTGAATGATTGAGAAAT
 CAGATGGCAAAATTTAGGATCCCTGATGACCCCACTAATTATAGAGACAACCAAGTGGTCAAGACCAAGAGAAAGTTTCTGA
 AAAATTCATTTAATCCAGATTTGGATCCTACAAAGAAGGACACAATTATGAAAACAACCATCATTTTCATATGAATACTCCCAAT
 CTTTTTATGAAAC

125P5C8(124P1B7/139P3A1) pCR2.1 subclone

ITSLWREILLESLLGCYSWSLYHDLGPMIYFPLQTLTGLEGSIAFLSPHFLTTPFWKLVNKKWMLTLRIITIGSIASFOAPNAKLRUM
 LALGVSSSLVQAVTWWSGSHLQRYLRWGFILGQMLVLRWYTSNPIWSYQMSNKKVLTLSAATLDRIGTDGDCSKPEEKKTGEVA
 GMASRPNWLLAGAAFGSLVFLTHWVFEVSLVSRWAVSGHPHPGPDNPFGGAVLLCLASGLMLPSCWFRGTGLWVWYGTASAA
 LLYLHTWAAVSGCVFAIFTASMWPOTLGLHINSNTNPGKMTIAMIFYLLEIFFCAWCTAFKFVPGGVYARERSVLLGTMMLIUNML
 SPKQNLDLLQTNSSKVLFRKSEKYMKLFLWLLVGVGLGLGRHKAYERKLGKVAPTKEYSAANWPFREFGYDNEGWSSLSERSAHL
 ETGADFTILESADSKPYMGNNDLTMWLGEKLGFTDFGPSTRYHTWGIMALSRYPIVKSEHLLPSPEGEIAPATLTVNISGKLVDFVY
 FGNHEDDLDRKLOAIYVSKLLKSSSNQVFLGYTSAFGSRDYLQLTEHGNVKDIDSTDHWRWCEYIMYRGURLGYARISHAELSDEI
 WAKFRIPDDPTNYRDNQKVVDHREVSEKHFNPRFGSYKEGHNYENIMHIFHMTNPKYFL

Steve Chappell Mitchell
 Associate Scientist
 Genesys
 11 Colorado Avenue
 La Jolla, CA 92037
 (310)820-8029 x281
 (310)820-8489
 smitchell@urogenesys.com
 www.urogenesys.com

Exhibit B**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

atgacctcgc tgtggagaga aatcctcttg gagtcgctgc tgggatgtgt ttcttgggtct SID#1
|||||
cg atgacctcgc tgtggagaga aatcctcttg gagtcgctgc tgggatgtgt ttcttgggtct Email

ctctaccatg acctgggacc gatgatctat tactttcctt tgcaaactcact agaactcact SID#1
|||||
ctctaccatg acctgggacc gatgatctat tactttcctt tgcaaactcact agaactcact Email

gggcttgaag gtttttagtat agcatttctt tctccaatat tcctaacaat tactcctttc SID#1
|||||
gggcttgaag gtttttagtat agcatttctt tctccaatat tcctaacaat tactcctttc Email

tggaaattgg ttaacaagaa gtggatgcta accctgctga ggataatcac tattggcagc SID#1
|||||
tggaaattgg ttaacaagaa gtggatgcta accctgctga ggataatcac tattggcagc Email

atagcctcct tccaggctcc aaatgccaaa cttcgactga tggttcttgc gcttgggggtg SID#1
|||||
atagcctcct tccaggctcc aaatgccaaa cttcgactga tggttcttgc gcttgggggtg Email

tcttcctcac tgatagtga agctgtgact tggtggtcgg gaagtcattt gcaaaggtag SID#1
|||||
tcttcctcac tgatagtga agctgtgact tggtggtcgg gaagtcattt gcaaaggtag Email

ctcagaattt ggggattcat tttaggacag attgttcttg ttgttctacg catatgggtat SID#1
|||||
ctcagaattt ggggattcat tttaggacag attgttcttg ttgttctacg catatgggtat Email

acttcactaa acccaatctg gagttatcag atgtccaaca aagtgatact gacattaagt SID#1
|||||
acttcactaa acccaatctg gagttatcag atgtccaaca aagtgatact gacattaagt Email

gccatagcca cacttgatcg tattggcaca gatggtgact gcagtaaacc tgaagaaaag SID#1
|||||
gccatagcca cacttgatcg tattggcaca gatggtgact gcagtaaacc tgaagaaaag Email

aagactggtg aggtagccac ggggatggcc tctagacca actggctgct ggcaggggct SID#1
|||||
aagactggtg aggtagccac ggggatggcc tctagacca actggctgct ggcaggggct Email

gcttttggtg gccttggtgt cctcaccac tgggtttttg gagaagtctc tcttggtttcc SID#1
|||||
gcttttggtg gccttggtgt cctcaccac tgggtttttg gagaagtctc tcttggtttcc Email

Exhibit B**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

agatgggcag tgagtgggca tccacatcca gggccagatc ctaaccatt tggaggtgca SID#1
||||||| ||||||| ||||||| ||||||| ||||||| |||||||
agatgggcag tgagtgggca tccacatcca gggccagatc ctaaccatt tggaggtgca Email

gtactgctgt gcttggcaag tggattgatg cttccatctt gtttgtggtt tcgtggtact SID#1
||||||| ||||||| ||||||| ||||||| ||||||| |||||||
gtactgctgt gcttggcaag tggattgatg cttccatctt gtttgtggtt tcgtggtact Email

ggtttgatct ggtgggttac aggaacagct tcagctgcgg ggctccttta cctgcacaca SID#1
||||||| ||||||| ||||||| ||||||| ||||||| |||||||
ggtttgatct ggtgggttac aggaacagct tcagctgcgg ggctccttta cctgcacaca Email

tgggcagctg ctgtgtctgg ctgtgtcttc gccatcttta ctgcatccat gtggcccca SID#1
||||||| ||||||| ||||||| ||||||| ||||||| |||||||
tgggcagctg ctgtgtctgg ctgtgtcttc gccatcttta ctgcatccat gtggcccca Email

acacttggac accttattaa ctcagggaca aaccctggga aaaccatgac cattgccatg SID#1
||||||| ||||||| ||||||| ||||||| ||||||| |||||||
acacttggac accttattaa ctcagggaca aaccctggga aaaccatgac cattgccatg Email

atattttatc ttctagaaat atttttctgt gcctgggtgca cagcttttaa gtttgtccca SID#1
||||||| ||||||| ||||||| ||||||| ||||||| |||||||
atattttatc ttctagaaat atttttctgt gcctgggtgca cagcttttaa gtttgtccca Email

ggaggtgtct acgctagaga aagatcagat gtgcttttgg ggacaatgat gttaattatc SID#1
||||||| ||||||| ||||||| ||||||| ||||||| |||||||
ggaggtgtct acgctagaga aagatcagat gtgcttttgg ggacaatgat gttaattatc Email

gggctgaata tgctatttgg tcctaagaaa aaccttgact tgcttcttca aacaaaaaac SID#1
||||||| ||||||| ||||||| ||||||| ||||||| |||||||
gggctgaata tgctatttgg tcctaagaaa aaccttgact tgcttcttca aacaaaaaac Email

agttctaaag tgcttttcag aaagagtga aaatacatga aactttttct gtggctgctt SID#1
||||||| ||||||| ||||||| ||||||| ||||||| |||||||
agttctaaag tgcttttcag aaagagtga aaatacatga aactttttct gtggctgctt Email

gttgggtgtgg gattgttggg attaggacta cggcataaag cctatgagag aaaactgggc SID#1
||||||| ||||||| ||||||| ||||||| ||||||| |||||||
gttgggtgtgg gattgttggg attaggacta cggcataaag cctatgagag aaaactgggc

Exhibit B**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

aaagtggcac caaccaaaga ggtctctgct gccatctggc ctttcagggt tggatatgac SID#1
||||| ||||||| ||||||| ||||||| ||||||| |||||||
aaagtggcac caaccaaaga ggtctctgct gccatctggc ctttcagggt tggatatgac Email

aatgaagggt ggtctagtct agaaagatca gctcacctgc tcaatgaaac aggtgcagat SID#1
||||| ||||||| ||||||| ||||||| ||||||| |||||||
aatgaagggt ggtctagtct agaaagatca gctcacctgc tcaatgaaac aggtgcagat Email

ttcataacaa ttttggagag tgatgcttct aagccctata tggggaacaa tgacttaacc SID#1
||||| ||||||| ||||||| ||||||| ||||||| |||||||
ttcataacaa ttttggagag tgatgcttct aagccctata tggggaacaa tgacttaacc Email

atgtggctag gggaaaagtt gggtttctat acagactttg gtccaagcac aaggtatcac SID#1
||||| ||||||| ||||||| ||||||| ||||||| |||||||
atgtggctag gggaaaagtt gggtttctat acagactttg gtccaagcac aaggtatcac Email

acttggggga ttatggcttt gtcaagatac ccaattgtga aatctgagca tcaccttctt SID#1
||||| ||||||| ||||||| ||||||| ||||||| |||||||
acttggggga ttatggcttt gtcaagatac ccaattgtga aatctgagca tcaccttctt Email

cgcgcaccag agggcgagat cgcaccagcc atcacattga ccgttaacat ttcgggcaag SID#1
||||| ||||||| ||||||| ||||||| ||||||| |||||||
cgcgcaccag agggcgagat cgcaccagcc atcacattga ccgttaacat ttcgggcaag Email

ctggtggatt ttgtcgtgac acactttggg aaccacgaag atgacctcga caggaaactg SID#1
||||| ||||||| ||||||| ||||||| ||||||| |||||||
ctggtggatt ttgtcgtgac acactttggg aaccacgaag atgacctcga caggaaactg Email

caggctattg ctgtttcaaa actactgaaa agtagctcta atcaagtgat atttctggga SID#1
||||| ||||||| ||||||| ||||||| ||||||| |||||||
caggctattg ctgtttcaaa actactgaaa agtagctcta atcaagtgat atttctggga Email

tatatcactt cagcacctgg ctccagagat tatctacagc tcaactgaaca tggcaatgtg SID#1
||||| ||||||| ||||||| ||||||| ||||||| |||||||
tatatcactt cagcacctgg ctccagagat tatctacagc tcaactgaaca tggcaatgtg Email

aaggatatcg acagcactga tcatgacaga tgggtgtgaat acattatgta tcgagggctg SID#1
||||| ||||||| ||||||| ||||||| ||||||| |||||||
aaggatatcg acagcactga tcatgacaga tgggtgtgaat acattatgta tcgagggctg Email

atcaggttgg gttatgcaag aatctcccat gctgaactga gtgattcaga aattcagatg SID#1
||||| ||||||| ||||||| ||||||| ||||||| |||||||
atcaggttgg gttatgcaag aatctcccat gctgaactga gtgattcaga aattcagatg

Exhibit B**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-------|
| gcaaaattta | ggatccctga | tgaccccact | aattatagag | acaaccagaa | agtgggcata | SID#1 |
| | | | | | | |
| gcaaaattta | ggatccctga | tgaccccact | aattatagag | acaaccagaa | agtgggcata | Email |

| | | | | | | |
|------------|------------|------------|-----------|------------|------------|-------|
| gaccacagag | aagtttctga | gaaaattcat | tttaatcca | gatttggatc | ctacaaagaa | SID#1 |
| | | | | | | |
| gaccacagag | aagtttctga | gaaaattcat | tttaatcca | gatttggatc | ctacaaagaa | Email |

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-------|
| ggacacaatt | atgaaaacaa | ccatcatttt | catatgaata | ctcccaaata | ctttttatga | SID#1 |
| | | | | | | |
| ggacacaatt | atgaaaacaa | ccatcatttt | catatgaata | ctcccaaata | ctttttatga | Email |

| | |
|-----|-------|
| aac | SID#1 |
| | |
| aac | Email |

Exhibit C**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Met Thr Ser Leu Trp Arg Glu Ile Leu Leu Glu Ser Leu Leu Gly (SID #2)
 | | | | | | | | | | | | | |
 Met Thr Ser Leu Trp Arg Glu Ile Leu Leu Glu Ser Leu Leu Gly (Email)

Cys Val Ser Trp Ser Leu Tyr His Asp Leu Gly Pro Met Ile Tyr Tyr (SID #2)
 | | | | | | | | | | | | | |
 Cys Val Ser Trp Ser Leu Tyr His Asp Leu Gly Pro Met Ile Tyr Tyr (Email)

Phe Pro Leu Gln Thr Leu Glu Leu Thr Gly Leu Glu Gly Phe Ser Ile (SID #2)
 | | | | | | | | | | | | | |
 Phe Pro Leu Gln Thr Leu Glu Leu Thr Gly Leu Glu Gly Phe Ser Ile (Email)

Ala Phe Leu Ser Pro Ile Phe Leu Thr Ile Thr Pro Phe Trp Lys Leu (SID #2)
 | | | | | | | | | | | | | |
 Ala Phe Leu Ser Pro Ile Phe Leu Thr Ile Trp Pro Phe Trp Lys Leu (Email)

Val Asn Lys Lys Trp Met Leu Thr Leu Leu Arg Ile Ile Thr Ile Gly (SID #2)
 | | | | | | | | | | | | | |
 Val Asn Lys Lys Trp Met Leu Thr Leu Leu Arg Ile Ile Thr Ile Gly (Email)

Ser Ile Ala Ser Phe Gln Ala Pro Asn Ala Lys Leu Arg Leu Met Val (SID #2)
 | | | | | | | | | | | | | |
 Ser Ile Ala Ser Phe Gln Ala Pro Asn Ala Lys Leu Arg Leu Met Val (Email)

Leu Ala Leu Gly Val Ser Ser Ser Leu Ile Val Gln Ala Val Thr Trp (SID #2)
 | | | | | | | | | | | | | |
 Leu Ala Leu Gly Val Ser Ser Ser Leu Ile Val Gln Ala Val Thr Trp (Email)

Trp Ser Gly Ser His Leu Gln Arg Tyr Leu Arg Ile Trp Gly Phe Ile (SID #2)
 | | | | | | | | | | | | | |
 Trp Ser Gly Ser His Leu Gln Arg Tyr Leu Arg Ile Trp Gly Phe Ile (Email)

Leu Gly Gln Ile Val Leu Val Val Leu Arg Ile Trp Tyr Thr Ser Leu (SID #2)
 | | | | | | | | | | | | | |
 Leu Gly Gln Ile Val Leu Val Val Leu Arg Ile Trp Tyr Thr Ser Leu (Email)

Asn Pro Ile Trp Ser Tyr Gln Met Ser Asn Lys Val Ile Leu Thr Leu (SID #2)
 | | | | | | | | | | | | | |
 Asn Pro Ile Trp Ser Tyr Gln Met Ser Asn Lys Val Ile Leu Thr Leu (Email)

Ser Ala Ile Ala Thr Leu Asp Arg Ile Gly Thr Asp Gly Asp Cys Ser (SID #2)
 | | | | | | | | | | | | | |
 Ser Ala Ile Ala Thr Leu Asp Arg Ile Gly Thr Asp Gly Asp Cys Ser (Email)

Exhibit C**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Lys Pro Glu Glu Lys Lys Thr Gly Glu Val Ala Thr Gly Met Ala Ser (SID #2)
 | | | | | | | | | | | | | | |
 Lys Pro Glu Glu Lys Lys Thr Gly Glu Val Ala Thr Gly Met Ala Ser (Email)

Arg Pro Asn Trp Leu Leu Ala Gly Ala Ala Phe Gly Ser Leu Val Phe (SID #2)
 | | | | | | | | | | | | | | |
 Arg Pro Asn Trp Leu Leu Ala Gly Ala Ala Phe Gly Ser Leu Val Phe (Email)

Leu Thr His Trp Val Phe Gly Glu Val Ser Leu Val Ser Arg Trp Ala (SID #2)
 | | | | | | | | | | | | | | |
 Leu Thr His Trp Val Phe Gly Glu Val Ser Leu Val Ser Arg Trp Ala (Email)

Val Ser Gly His Pro His Pro Gly Pro Asp Pro Asn Pro Phe Gly Gly (SID #2)
 | | | | | | | | | | | | | | |
 Val Ser Gly His Pro His Pro Gly Pro Asp Pro Asn Pro Phe Gly Gly (Email)

Ala Val Leu Leu Cys Leu Ala Ser Gly Leu Met Leu Pro Ser Cys Leu (SID #2)
 | | | | | | | | | | | | | | |
 Ala Val Leu Leu Cys Leu Ala Ser Glu Leu Met Leu Pro Ser Cys Leu (Email)

Trp Phe Arg Gly Thr Gly Leu Ile Trp Trp Val Thr Gly Thr Ala Ser (SID #2)
 | | | | | | | | | | | | | | |
 Trp Phe Arg Gly Thr Gly Leu Ile Trp Trp Val Thr Gly Thr Ala Ser (Email)

Ala Ala Gly Leu Leu Tyr Leu His Thr Trp Ala Ala Ala Val Ser Gly (SID #2)
 | | | | | | | | | | | | | | |
 Ala Ala Gly Leu Leu Tyr Leu His Thr Trp Ala Ala Ala Val Ser Gly (Email)

Cys Val Phe Ala Ile Phe Thr Ala Ser Met Trp Pro Gln Thr Leu Gly (SID #2)
 | | | | | | | | | | | | | | |
 Cys Val Phe Ala Ile Phe Thr Ala Ser Met Trp Pro Gln Thr Leu Gly (Email)

His Leu Ile Asn Ser Gly Thr Asn Pro Gly Lys Thr Met Thr Ile Ala (SID #2)
 | | | | | | | | | | | | | | |
 His Leu Ile Asn Ser Gly Thr Asn Pro Gly Lys Thr Met Thr Ile Ala (Email)

Met Ile Phe Tyr Leu Leu Glu Ile Phe Phe Cys Ala Trp Cys Thr Ala (SID #2)
 | | | | | | | | | | | | | | |
 Met Ile Phe Tyr Leu Leu Glu Ile Phe Phe Cys Ala Trp Cys Thr Ala (Email)

Phe Lys Phe Val Pro Gly Gly Val Tyr Ala Arg Glu Arg Ser Asp Val (SID #2)
 | | | | | | | | | | | | | | |
 Phe Lys Phe Val Pro Gly Gly Val Tyr Ala Arg Glu Arg Ser Asp Val (Email)

Exhibit C**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Leu Leu Gly Thr Met Met Leu Ile Ile Gly Leu Asn Met Leu Phe Gly (SID #2)
 | | | | | | | | | | | | | | |
 Leu Leu Gly Thr Met Met Leu Ile Ile Gly Leu Asn Met Leu Phe Gly (Email)

Pro Lys Lys Asn Leu Asp Leu Leu Leu Gln Thr Lys Asn Ser Ser (SID #2)
 | | | | | | | | | | | | | | |
 Pro Lys Lys Asn Leu Asp Leu Leu Leu Gln Thr Lys Asn Ser Ser (Email)

Lys Val Leu Phe Arg Lys Ser Glu Lys Tyr Met Lys Leu Phe Leu Trp (SID #2)
 | | | | | | | | | | | | | | |
 Lys Val Leu Phe Arg Lys Ser Glu Lys Tyr Met Lys Leu Phe Leu Trp (Email)

Leu Leu Val Gly Val Gly Leu Leu Gly Leu Gly Leu Arg His Lys Ala (SID #2)
 | | | | | | | | | | | | | | |
 Leu Leu Val Gly Val Gly Leu Leu Gly Leu Gly Leu Arg His Lys Ala (Email)

Tyr Glu Arg Lys Leu Gly Lys Val Ala Pro Thr Lys Glu Val Ser Ala Ala (SID #2)
 | | | | | | | | | | | | | | |
 Tyr Glu Arg Lys Leu Gly Lys Val Ala Pro Thr Lys Glu Val Ser Ala Ala (Email)

Ile Trp Pro Phe Arg Phe Gly Tyr Asp Asn Glu Gly Trp Ser Ser (SID #2)
 | | | | | | | | | | | | | | |
 Ile Trp Pro Phe Arg Phe Gly Tyr Asp Asn Glu Gly Trp Ser Ser (Email)

Leu Glu Arg Ser Ala His Leu Leu Asn Glu Thr Gly Ala Asp Phe Ile (SID #2)
 | | | | | | | | | | | | | | |
 Leu Glu Arg Ser Ala His Leu Leu Asn Glu Thr Gly Ala Asp Phe Ile (Email)

Thr Ile Leu Glu Ser Asp Ala Ser Lys Pro Tyr Met Gly Asn Asn Asp (SID #2)
 | | | | | | | | | | | | | | |
 Thr Ile Leu Glu Ser Asp Ala Ser Lys Pro Tyr Met Gly Asn Asn Asp (Email)

Leu Thr Met Trp Leu Gly Glu Lys Leu Gly Phe Tyr Thr Asp Phe Gly (SID #2)
 | | | | | | | | | | | | | | |
 Leu Thr Met Trp Leu Gly Glu Lys Leu Gly Phe Tyr Thr Asp Phe Gly (Email)

Pro Ser Thr Arg Tyr His Thr Trp Gly Ile Met Ala Leu Ser Arg Tyr (SID #2)
 | | | | | | | | | | | | | | |
 Pro Ser Thr Arg Tyr His Thr Trp Gly Ile Met Ala Leu Ser Arg Tyr (Email)

Pro Ile Val Lys Ser Glu His His Leu Leu Pro Ser Pro Glu Gly Glu (SID #2)
 | | | | | | | | | | | | | | |
 Pro Ile Val Lys Ser Glu His His Leu Leu Pro Ser Pro Glu Gly Glu (Email)

Exhibit C**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Ile Ala Pro Ala Ile Thr Leu Thr Val Asn Ile Ser Gly Lys Leu Val (SID #2)
 | | | | | | | | | | | | | | | |
 Ile Ala Pro Ala Ile Thr Leu Thr Val Asn Ile Ser Gly Lys Leu Val (Email)

Asp Phe Val Val Thr His Phe Gly Asn His Glu Asp Asp Leu Asp Arg (SID #2)
 | | | | | | | | | | | | | | | |
 Asp Phe Val Val Thr His Phe Gly Asn His Glu Asp Asp Leu Asp Arg (Email)

Lys Leu Gln Ala Ile Ala Val Ser Lys Leu Leu Lys Ser Ser Ser Asn (SID #2)
 | | | | | | | | | | | | | | | |
 Lys Leu Gln Ala Ile Ala Val Ser Lys Leu Leu Lys Ser Ser Ser Asn (Email)

Gln Val Ile Phe Leu Gly Tyr Ile Thr Ser Ala Pro Gly Ser Arg Asp (SID #2)
 | | | | | | | | | | | | | | | |
 Gln Val Ile Phe Leu Gly Tyr Ile Thr Ser Ala Pro Gly Ser Arg Asp

Tyr Leu Gln Leu Thr Glu His Gly Asn Val Lys Asp Ile Asp Ser Thr (SID #2)
 | | | | | | | | | | | | | | | |
 Tyr Leu Gln Leu Thr Glu His Gly Asn Val Lys Asp Ile Asp Ser Thr (Email)

Asp His Asp Arg Trp Cys Glu Tyr Ile Met Tyr Arg Gly Leu Ile Arg (SID #2)
 | | | | | | | | | | | | | | | |
 Asp His Asp Arg Trp Cys Glu Tyr Ile Met Tyr Arg Gly Leu Ile Arg (Email)

Leu Gly Tyr Ala Arg Ile Ser His Ala Glu Leu Ser Asp Ser Glu Ile (SID #2)
 | | | | | | | | | | | | | | | |
 Leu Gly Tyr Ala Arg Ile Ser His Ala Glu Leu Ser Asp Ser Glu Ile (Email)


Gln Met Ala Lys Phe Arg Ile Pro Asp Asp Pro Thr Asn Tyr Arg Asp (SID #2)
 | | | | | | | | | | | | | | | |
 Gln Met Ala Lys Phe Arg Ile Pro Asp Asp Pro Thr Asn Tyr Arg Asp (Email)

Asn Gln Lys Val Val Ile Asp His Arg Glu Val Ser Glu Lys Ile His (SID #2)
 | | | | | | | | | | | | | | | |
 Asn Gln Lys Val Val Ile Asp His Arg Glu Val Ser Glu Lys Ile His (SID #2)

Phe Asn Pro Arg Phe Gly Ser Tyr Lys Glu Gly His Asn Tyr Glu Asn (SID #2)
 | | | | | | | | | | | | | | | |
 Phe Asn Pro Arg Phe Gly Ser Tyr Lys Glu Gly His Asn Tyr Glu Asn (Email)

Asn His His Phe His Met Asn Thr Pro Lys Tyr Phe Leu (SID #2)
 | | | | | | | | | | | | | | | |
 Asn His His Phe His Met Asn Thr Pro Lys Tyr Phe Leu (Email)

Waybill #: 15170591752

Origin: **SBP**
Date Printed: 3/3/2006

Webship API 02.00 (01/2004)

| | |
|--|---|
| To: Steve Chappell Mitchell 601 Linden Place, #311 Evanston, IL 60202 UNITED STATES Attention To: Steve Chappell Mitchell Phone #: (310) 820-8029 | Service: E Special Service: Route: SKOF 3B |
|--|---|


From:
AGENSYS
1545 17TH STREET
SANTA MONICA, CA 90404
UNITED STATES
Description:
Weight (lbs.): Letter **Dims: 0 X 0 X 0**
Pieces: 1 of 1
Bill Shipment To: Sender
Ship Ref: 6600- Gen Intellect Prop.

Sent By: Shane Popp
Phone #: 310-820-8029

Please fold or cut in half

DO NOT PHOTOCOPY

Using a photocopy could delay the delivery of your package and will result in additional shipping charge

Create New ShipmentView Pending Shipments**SENDER'S RECEIPT****Airbill#:** 15170591752**To(Company):**
Steve Chappell Mitchell
601 Linden Place, #311
Evanston, IL 60202
United States
Attention To: Steve Chappell Mitchell
Phone#: (310) 820-8029
Sent By: Shane Popp**Phone#:** 310-820-8029
Rate Estimate: 13.47
Protection: None Required **Amount: \$0**
Description:
Weight: Letter
Dimensions: 0 X 0 X 0
Ship Ref: 6600- Gen Intellect Prop.
Service Level: Express
(Next business day by 12 PM)
Special Service:
COD Amount: \$0.00
Payment Options:
Date Printed: 2006-03-03
Bill Shipment To: Sender
Bill To Account: 782042209
Ship Date: 2006-03-03

DHL Signature (optional) _____ **Route** _____ **Date** _____ **Time** _____

 For Tracking, please go to www.dhl-usa.com or call 1-800-CALL-DHL
 Thank you for shipping with DHL Worldwide Express

Conte



DHL USA Hom

[Return to DHLUSA](#)

Track results detail

Tracking results detail for 15170591752

Tracking summary

Current Status **Shipment delivered.** [View Signature](#)

Delivered on 3/6/2006 11:35 am

Delivered to Residence Door

Signed for by LD FD -601 LINDEN PL [What is this?](#)

Tracking history

| Date and Time | Status | Location |
|-------------------|--------------------------|-------------------|
| 3/6/2006 11:35 am | Shipment delivered. | Franklin Park, IL |
| 3/4/2006 8:05 am | Arrived at DHL facility. | Franklin Park, IL |
| 3/3/2006 5:11 pm | Departing origin. | Santa Monica, CA |
| 4:10 pm | Picked Up by DHL. | Shipper's Door |

| | | |
|---|---|--|
| Ship From: AGENSYS Santa Monica, CA 90404 United States | Ship To: STEVE CHAPPELL MITCHELL Evanston, IL 60202 United States | Shipment Information: Ship date: 3/3/2006 Pieces: 1 Total weight: 1 lb Ship Type: Package Shipment Reference: 61 INTELLECT PROP. Service: Next Day Special Service: Description: |
| Attention: AGENSYS | Attention: STEVE CHAPPELL MITCHELL | |

Tracking detail provided by DHL: 3/8/2006, 9:35:58 am pt.

[Track new](#)

You are authorized to use DHL tracking systems solely to track shipments tendered by or for you to [use of DHL tracking systems and information is strictly prohibited.

New to DHL?

Registration is quick and easy. And as a registered user, you'll have access to services and tools to help you ship your packages easily and efficiently.


[Register Now](#)

Questions?

We're here to help!
[Contact DHL](#)

[Conte](#)

DHL USA Hom



Delivery Signature Detail

Track

- ▶ Track by number
- ▶ Track by reference
- ▶ Get delivery signature
- ▶ Track DHL Same Day service

Log in to DHL

User ID Password ☐ Remember my User ID

Log in

▶ Forgot your Password?

Tracking Delivery Signature details...Tracking
Number 15170591752

▶ Help

New to DHL?

Registration is
And as a regist
have access to
tools to help yo
packages easil
▶ Register Now

Tracking summary


Current Status **✓ Shipment Delivered**

Delivered on 3/6/06 11:35 am

Delivered to Residence Door

Signed for by **LD ED -601 LINDEN PL** Help me with the signed by codes

Signature



For a description of the code above, please click here.

Receiver Information

Please retry later to obtain receiver information.

Tracking detail provided by DHL: 3/8/2006 9:36:28 AM

View Tracking
Detail E-mail Delivery
Signature Track new
shipment

You are authorized to use DHL tracking systems solely to track shipments
tendered by or for you to DHL. Any other use of DHL tracking systems and
information is strictly prohibited.

DHL Global | About DHL | Newsroom | Contact | Sitemap | Privacy Policy
Copyright © 2006 DHL International, Ltd. All Rights Reserved.